Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified

Phibro Animal Health

(

PAHC

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Phibro Animal Health as such a stock due to the following factors:

  • PAHC has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $7.8 million.
  • PAHC has traded 4,433 shares today.
  • PAHC is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in PAHC with the Ticky from Trade-Ideas. See the FREE profile for PAHC NOW at Trade-Ideas

More details on PAHC:

Phibro Animal Health Corporation operates as a diversified developer, manufacturer, and marketer of a range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy, and aquaculture. The stock currently has a dividend yield of 1.1%. PAHC has a PE ratio of 204. Currently there are 3 analysts that rate Phibro Animal Health a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Recommends

The average volume for Phibro Animal Health has been 161,500 shares per day over the past 30 days. Phibro Animal Health has a market cap of $643.6 million and is part of the health care sector and health services industry. Shares are up 16.6% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Phibro Animal Health as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, notable return on equity and revenue growth. However, as a counter to these strengths, we also find weaknesses including poor profit margins and generally higher debt management risk.

Highlights from the ratings report include:

  • Powered by its strong earnings growth of 206.25% and other important driving factors, this stock has surged by 68.21% over the past year, outperforming the rise in the S&P 500 Index during the same period.
  • Compared to other companies in the Pharmaceuticals industry and the overall market, PHIBRO ANIMAL HEALTH CORP's return on equity significantly exceeds that of both the industry average and the S&P 500.
  • PHIBRO ANIMAL HEALTH CORP reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This year, the market expects an improvement in earnings ($1.66 versus -$0.29).
  • The debt-to-equity ratio is very high at 12.45 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Even though the debt-to-equity ratio is weak, PAHC's quick ratio is somewhat strong at 1.29, demonstrating the ability to handle short-term liquidity needs.
  • The gross profit margin for PHIBRO ANIMAL HEALTH CORP is currently lower than what is desirable, coming in at 34.35%. Regardless of PAHC's low profit margin, it has managed to increase from the same period last year. Despite the mixed results of the gross profit margin, PAHC's net profit margin of 10.36% is significantly lower than the industry average.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.